Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...

Finbold has selected three interesting pharmaceutical stocks that could see significant moves to the upside in 2025.

Neither coffee drinking pattern was tied to more or less cancer-specific mortality.

Shares of Eli Lilly & Co. LLY rose 1.07% to $773.29 Tuesday, on what proved to be an all-around grim trading session for the ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 478.78% and ...

North Dakota lawmakers on Thursday will hear testimony on a bill to lower the price of insulin drugs and supplies for ...

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

Summit Partners has hired Ricardo Gonzalez as a partner on the firm’s growth products and services team.

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...